

Research Compliance Activity and Turn-Around-Time (TAT) Summary Report
Fiscal Year 2022 (7/1/2021 to 6/30/2022)

TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.

Institutional Biosafety Committee (IBC) - Bloomington								
	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median
Full Board								
New Studies - Full Board (to review)	30.9	34.0	30.0	23.0	31.3	30.0	29.0	29.0
New Studies - Full Board (to approval)	71.3	57.0	59.1	53.5	50.6	53.0	61.7	59.0
Exempt								
New Studies - Exempt (to determination)	37.3	38.0	42.2	37.5	28.6	41.0	39.5	39.5
Amendments								
Amendments - Minor	6.8	1.0	4.4	1.0	3.9	2.0	4.8	2.0
Amendments - Major	15.0	18.0	63.0	63.0	17.0	14.0	21.5	19.0

*Note: TAT includes a "pre-review" time frame occurring prior to full committee meeting.

Area Activities/Throughput (T)	Q1 (Jul-Sep)			Q2 (Oct-Dec)			Q3 (Jan-Mar)			Q4 (Apr-Jun)		
	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged
New Studies - Full Board	8	8	0	7	8	1	3	5	2	1	3	2
New Studies - Exempt	3	3	0	8	6	-2 (25.0%)	1	3	2	1	2	1
Amendments - Minor	42	41	-1 (2.4%)	35	33	-2 (5.7%)	31	40	9	48	45	-3 (6.3%)
Amendments - Major	4	4	0	1	1	0	4	4	0	8	7	-1 (12.5%)
Continuing Reviews	31	33	2	26	26	0	25	23	-2 (8.0%)	37	34	-3 (8.1%)
TOTAL	88	89	1 (-1.1%)	77	74	-3 (3.9%)	64	75	11 (-17.2%)	95	91	-4 (4.2%)

Area Training Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Presentations (# of events)	0	0	0	0	0

Reportable Events/Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Immediate OBA Report	0	0	0	0	0
30 Day OBA Report	0	0	0	0	0
Lab Accident/Injury/Exposure	0	0	0	1	1

Reporting Agency: NIH Office of Biotechnology Activities (OBA)